A Food and Drug Administration panel in April will review Merck’s Arcoxia, its follow-up to the controversial painkiller Vioxx, which was pulled from the market in 2004 following safety concerns.
A Food and Drug Administration panel in April will review Merck’s Arcoxia, its follow-up to the controversial painkiller Vioxx, which was pulled from the market in 2004 following safety concerns.
